In 2024, Brazilian police seized 609 units of illegal weight-loss drugs. In 2025 they seized 60,787. The Brazil weight-loss pen black market now looks like one of the fastest-growing contraband trades in Latin America, and Brazil’s own regulator thinks the fix is cheaper, legal pens rather than more raids alone.
Bloomberg’s Rachel Gamarski covered the boom in a video report on 20 October 2026. Here is the data behind it, and what could come next.
Key takeaways
- Seizures of illegal GLP-1 pens rose from 609 units in 2024 to 60,787 in 2025, and more than 54,000 more were seized in the first three months of 2026.
- Itaú BBA estimates that about 51% of Brazil’s roughly $7 billion weight-loss drug market in 2026 comes from untracked sources.
- Most smuggled product crosses from Paraguay, where looser patent rules let local firms make tirzepatide copies.
- Ozempic’s Brazilian patent expired on 20 March 2026, and Anvisa has since approved cheaper local semaglutide pens.
How big is Brazil’s weight-loss pen black market?
Big, and nobody agrees on the exact size. That disagreement is itself a clue. A market this informal is hard to measure.
The Federal Pharmacy Council (CFF) cited the Anuário da Falsificação, which estimates that counterfeit, smuggled and pirated weight-loss drugs moved about R$4.6 billion in 2025. The council also says four in five weight-loss pens sold in Brazil are illegal. The retail data firm Scanntech puts the illegal share closer to half.
Demand explains the scale. According to Euromonitor figures cited by Reuters, 5.5% of Brazilians use GLP-1 drugs, against a global average of 3.7%. GLP-1 drugs mimic a gut hormone that controls appetite and blood sugar. The class includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro).
Where do the illegal pens come from?
Mostly from Paraguay. Its patent rules are looser, so local firms can legally make tirzepatide products that cost far more as branded drugs in Brazil. One Paraguayan product, sold as “T.G.” and approved by the regulator Dinavisa, has never been evaluated by Brazilian authorities.
Smugglers have been creative. In April 2026, customs officers searched a tourist bus from Paraguay and found tirzepatide vials hidden in jars of dulce de leche. The haul came to more than 2,500 vials. Other shipments turned up in motorcycle exhaust pipes and fake shoe soles.
Data obtained by Fiquem Sabendo through Brazil’s access-to-information law tells the same story. The Federal Revenue Service seized 8 pens in all of 2023 and more than 130,000 in the first half of 2026, worth almost R$47 million. About 90,000 of those were seized in Paraná, the state that borders Paraguay.
The numbers, side by side
Each agency counts in its own way, so the figures don’t add up neatly. Here are the main ones:
| Source | Period | Figure |
|---|---|---|
| Federal Police / anti-counterfeiting data | 2024 | 609 units seized |
| Federal Police / anti-counterfeiting data | 2025 | 60,787 units seized |
| Federal Police | January to March 2026 | 54,577 units seized |
| Federal Highway Police (PRF) | January to May 2026 | About 46,000 pens and ampoules in 311 seizures |
| Federal Revenue Service | First half of 2026 | More than 130,000 pens, worth almost R$47 million |
The biggest single Revenue Service bust so far was 72,000 tirzepatide pens in Paraná, valued at R$16.6 million. Tirzepatide is the dominant contraband. Between 2023 and early 2026, about 111,000 of the seized units were tirzepatide pens, compared with 963 semaglutide units.
Why are buyers taking the risk?
The main reason is price. Branded pens are expensive in Brazil, so buyers turn to cheaper versions that skip registration and quality checks. Influencers who promote compounded products (drugs mixed by pharmacies rather than made by the original manufacturer) add to the pull, according to Andreia Kohout of the Brazilian Anti-Counterfeiting Association.
Think of it like a fake designer bag, except this one gets injected. With a bag, the worst outcome is bad stitching. With an injectable, you can’t see if the contents are wrong, if the dose is off, or if the pen was stored in a hot car boot for a week. Doctors quoted by Reuters flagged heat and poor storage as real risks.
Brazil recorded more than 3,600 complications linked to weight-loss drugs between 2018 and mid-August 2026, and over 60% of those reports came in 2025 and 2026. Authorities are investigating 83 deaths, though Reuters could not determine how many involved unauthorized products.
What are Brazilian authorities doing?
Raids, bans and tighter pharmacy rules. On 7 April 2026, the Federal Police and Anvisa, Brazil’s health regulator, launched Operation Heavy Pen. It served 45 search warrants across about a dozen states, targeting compounding labs, aesthetic clinics and suspect companies, SBT News reported. Agents also found retatrutide, an experimental drug that no regulator in the world has approved.
Anvisa has ordered several unregistered brands off the market during 2026, including Lipoless, Gluconex and Tirzedral, and it flagged a counterfeit Mounjaro batch. It now also requires pharmacies to retain prescriptions when they sell these drugs.
If you want to watch for counterfeit-drug warnings yourself, our guide to tracking FDA recalls with Python shows how to build an automated recall alert. It covers the US, but the same idea works with any regulator that publishes its data.
What happens next?
The real test is price. Novo Nordisk’s Brazilian semaglutide patent expired on 20 March 2026. In May, Anvisa approved Ozivy from local drugmaker EMS, the first domestically made semaglutide pen. The company lists it at about R$333 through its loyalty programme, and Reuters put a four-week supply at under $100.
More rivals followed. In August 2026, Anvisa approved Brazil’s first generic semaglutide from EMS and a second from Germed. Hypera’s Semavy and a Biolab-Sandoz pen are also in the pipeline.
My view: this probably won’t empty the black market quickly. Most contraband is tirzepatide, and cheap semaglutide doesn’t directly replace it. The thing to watch is whether legal prices fall far enough that a smuggled vial stops looking like a bargain.
FAQ
Why is Paraguay the main source of illegal pens?
Paraguay’s looser patent laws let local companies make drugs such as tirzepatide that are patented and pricier in Brazil. The products are then smuggled across the border, mostly into Paraná.
Did Ozempic lose its patent in Brazil?
Yes. The semaglutide patent expired on 20 March 2026. Anvisa approved EMS’s Ozivy in May 2026 and the first generics in August 2026.
How much of Brazil’s market is illegal?
Estimates vary. Itaú BBA says about 51% of the roughly $7 billion market in 2026 comes from untracked sources. The Federal Pharmacy Council says four in five pens sold are illegal.
Next step: if you follow pharma stocks, watch the first generic semaglutide price announcements in Brazil. They will show whether legal pens can compete with the border trade.
This article is for information only and is not investment advice.
Leave a comment